

Medicine: pembrolizumab (brand name: Keytruda[®]) for treating stage 3 melanoma after surgery

Merck Sharp & Dohme UK Ltd

What is pembrolizumab for?

Pembrolizumab was considered for use to treat patients with melanoma, which is a type of skin cancer. It is used to treat adult patients who have had surgery to remove the melanoma that had previously spread to the lymph nodes (stage 3 melanoma).

How does pembrolizumab work?

Pembrolizumab is an immunotherapy. This is a type of cancer treatment that stimulates the immune system (the body's natural defence system) to fight the cancer. Some cancer cells produce proteins that switch off certain immune cells (called T-cells). Pembrolizumab attaches to these T-cells, which stops the cancer switching them off, and helps the immune system fight the cancer.

What has SMC said?

SMC has accepted pembrolizumab for the treatment of patients with melanoma, as described above.



Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.

- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration, applying extra flexibility because pembrolizumab is a medicine for a rare condition, and after the company applied a confidential discount to the cost of the medicine, SMC was able to accept it as a possible treatment within NHSScotland.

What does SMC's decision mean for me?

If your healthcare professional thinks that pembrolizumab for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland. For further information see:

Medicines in Scotland: What's the right treatment for me?

www.healthcareimprovementscotland.org/medicinesbooklet.aspx



More information

The organisations below can provide more information and support for people with melanoma and their families. SMC is not responsible for the content of any information provided by external organisations.

Melanoma Action and Support Scotland (MASScot)



<http://www.masscot.org.uk>



0141 946 2017

Melanoma UK



<http://www.melanomauk.org.uk>



0808 171 2455

You can find out more about pembrolizumab in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>

Date advice published: 13 May 2019

SMC No: (SMC2144)